Regenxbio (RGNX) Cash from Investing Activities (2015 - 2025)

Regenxbio's Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $37.5 million for Q4 2025.

• In Q4 2025, Cash from Investing Activities fell 6.79% year-over-year to $37.5 million; the TTM figure through Dec 2025 stood at -$15.9 million (down 115.34% YoY), while the FY2025 annual figure was -$15.9 million, down 115.34% from the prior year.
• Cash from Investing Activities was $37.5 million for Q4 2025 at Regenxbio, down from $42.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $63.1 million in Q1 2023 to a low of -$216.4 million in Q4 2021.
• Historically, Cash from Investing Activities has averaged -$7.0 million across 5 years, with a median of $30.3 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 5208.05% in 2023, then plunged 52301.49% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$216.4 million in 2021, then surged by 112.34% to $26.7 million in 2022, then grew by 27.24% to $34.0 million in 2023, then gained by 18.54% to $40.3 million in 2024, then fell by 6.79% to $37.5 million in 2025.
• The last three Cash from Investing Activities figures came in at $37.5 million (Q4 2025), $42.3 million (Q3 2025), and -$140.4 million (Q2 2025), per Business Quant data.